<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04584242</url>
  </required_header>
  <id_info>
    <org_study_id>4-2019-0305</org_study_id>
    <nct_id>NCT04584242</nct_id>
  </id_info>
  <brief_title>Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes</brief_title>
  <official_title>Prospective, Multicenter, Randomized, and Comparative Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical study determines the effect of Evogliptin in patients with type 2 diabetes&#xD;
      mellitus and chronic hepatitis B to confirm the improvement of hepatic fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline LSM (Liver Stiffness measurement) at week 24 (±7days)</measure>
    <time_frame>Baseline</time_frame>
    <description>Changes in the Liver Stiffness measurement after 24 weeks (±7days) compared to Baseline within and between arms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline LSM (Liver Stiffness measurement) at week 24 (±7days)</measure>
    <time_frame>Baseline to 24 weeks (±7days)</time_frame>
    <description>Changes in the Liver Stiffness measurement after 24 weeks (±7days) compared to Baseline within and between arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline CAP (Controlled Attenuation Parameter) at week 24 (±7days) within and between arms</measure>
    <time_frame>1) Baseline, 2) Baseline to 24 weeks (±7days)</time_frame>
    <description>Change from baseline at Week 24 (±7days) is defined as [(Baseline CAP value) - (Follow-up CAP value)] / (Baseline CAP value) * 100 (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline HbA1c at week 24 (±7days) within and between arms</measure>
    <time_frame>1) Baseline, 2) Baseline to 24 weeks (±7days)</time_frame>
    <description>Change from baseline at Week 24 (±7days) is defined as HbA1c at Week 24 (±7days) minus HbA1c at Week 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline Insulin at week 24 (±7days) within and between arms</measure>
    <time_frame>1) Baseline, 2) Baseline to 24 weeks (±7days)</time_frame>
    <description>Change from baseline at Week 24 (±7days) is defined as insulin at Week 24 (±7days) minus insulin at Week 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline lipid profile (total cholesterol, HDL, LDL, TG) at week 24 (±7days) within and between arms</measure>
    <time_frame>1) Baseline, 2) Baseline to 24 weeks (±7days)</time_frame>
    <description>Change from baseline at Week 24 (±7days) is defined as lipid profile (total cholesterol, HDL, LDL, TG) at Week 24 (±7days) minus lipid profile at Week 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline AST/ALT at week 24 (±7days) within and between arms</measure>
    <time_frame>1) Baseline, 2) Baseline to 24 weeks (±7days)</time_frame>
    <description>Change form baseline at Week 24 (±7days) is defined as the proportion of AST/ALT values who are normalized at Week 24 (±7days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline Body weight at week 24 (±7days) within and between arms</measure>
    <time_frame>1) Baseline, 2) Baseline to 24 weeks (±7days)</time_frame>
    <description>Change from baseline at Week 24 (±7days) is defined as body weight at Week 24 minus body weight at Week 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline Liver fibrosis and fatty liver at week 24 (±7days) among the MRE+MRI PDFF enforcement arms within and between arms</measure>
    <time_frame>1) Baseline, 2) Baseline to 24 weeks (±7days)</time_frame>
    <description>Change from baseline at Week 24 (±7days) is defined by MRE+MRI PDFF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of adverse effects and drug interruptions or changes between baseline and week 24 (±7days) within and between arms</measure>
    <time_frame>1) Baseline, 2) Baseline to 24 weeks (±7days)</time_frame>
    <description>Compare between baseline at Week 24 (±7days) is defined as the occurrence rate of adverse events and drug interruptions or changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic factor of the Improvement of Liver fibrosis between baseline and week 24 (±7days) within and between arms</measure>
    <time_frame>1) Baseline, 2) Baseline to 24 weeks (±7days)</time_frame>
    <description>Prediction Factor Analysis of the Improvement of Liver fibrosis after 24 (±7days) weeks compared to Baseline within and between arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic factor of the Improvement of Fatty liver between baseline and week 24 (±7days) within and between arms</measure>
    <time_frame>1) Baseline, 2) Baseline to 24 weeks (±7days)</time_frame>
    <description>Prediction Factor Analysis of the Improvement of Fatty liver after 24 weeks (±7days) compared to Baseline within and between arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic factor of the Improvement of HbA1 between baseline and week 24 (±7days) within and between arms</measure>
    <time_frame>1) Baseline, 2) Baseline to 24 weeks (±7days)</time_frame>
    <description>Prediction Factor Analysis of the Improvement of HbA1c after 24 weeks (±7days) compared to Baseline within and between arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Evogliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gluconon tab 15mg</intervention_name>
    <description>frosting and formulation : a round, convex tablet of white to gray. path of administration : once a day, two tabs, oral Amount of raw material medication (1 pill) : Pioglitazone hydrochloride 16.53mg storage method : Store 15 to 30°C to avoid light-tight containers and moisture manufacturing source : DONG-A ST</description>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>suganon tab 5mg</intervention_name>
    <description>frosting and formulation : pink circular film coating tablets path of administration : once a day, one tabs, oral Amount of raw material medication (1 pill) : Evogliptin tartrate 6.869mg(5mg as evogliptin) storage method : Confidential containers, stored at room temperature (1-30°C) manufacturing source : DONG-A ST</description>
    <arm_group_label>Evogliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adultes between 20 and 80 years of age&#xD;
&#xD;
          -  Patients who satisfy the following conditions among chronic hepatitis B patients&#xD;
             diagnosed with type 2 diabetes&#xD;
&#xD;
               1. Patients who are newly diagnosed as type 2 diabetes : 6.5% ≤ HbA1c &lt; 10.0%&#xD;
&#xD;
               2. Patients who are already diagnosed as type 2 diabetes: HbA1c &lt; 10.0%&#xD;
&#xD;
          -  Patients who have significant liver fibrosis of at least 7 kPa in a hepaticity test&#xD;
             using fibroscan&#xD;
&#xD;
          -  Patients who voluntarily signed the consent form after informed on the object, method,&#xD;
             benefits and risks of the clinical study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who were taking Pioglitazone or Evoglipitin medication or who took diabetes&#xD;
             medication within 4 weeks at the time&#xD;
&#xD;
          -  Patients who meet the standard of alcoholic fatty liver (in excess of 210g per week&#xD;
             for men and 140g per week for women over the last two years)&#xD;
&#xD;
          -  Liver cirrhosis patients with impaired liver function (CTP class B and C)&#xD;
&#xD;
          -  Patients who took drugs that can cause fatty liver (amiodarone, methotrexate,&#xD;
             tamoxifen, valproate, corticosteroids, etc.)&#xD;
&#xD;
          -  Patients with acute or chronic metabolic acidosis with or without coma and history of&#xD;
             ketonic acid (within 24 weeks)&#xD;
&#xD;
          -  Allergic or hypersensitive to the target drug or its composition;&#xD;
&#xD;
          -  Patients treated with oral or non - oral corticosteroid treatment for chronic (more&#xD;
             than 14 consecutive days) within 8 weeks prior to screening.&#xD;
&#xD;
          -  Poor nutrition, starvation, and debilitating conditions (including severe infections&#xD;
             and severe injury patients before and after surgery)&#xD;
&#xD;
          -  Patients who are receiving radiation and chemotherapy for malignant tumors or patients&#xD;
             who have been on chemotherapy or radiation treatment for less than two years.&#xD;
&#xD;
          -  Patients with heart failure in 24 weeks (class III to IV in NYHA classification) or&#xD;
             unregulated arrhythmia.&#xD;
&#xD;
          -  Patients with acute cardiovascular disease in 12 weeks or less (e.g. unstable angina,&#xD;
             myocardial infarction, routine ischemic seizures, cerebrovascular disease, coronary&#xD;
             bypass surgery, or coronary artery interventions).&#xD;
&#xD;
          -  Patients with renal failure, chronic neuropathy (estimated glomerular filtration rate&#xD;
             &lt;60 mL/min/1.73 m2) or dialysis&#xD;
&#xD;
          -  Anemia patients whose Hb levels are less than 10.5g/dl&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Patients who do not agree to use proper contraception during clinical trials only for&#xD;
             women or men.&#xD;
&#xD;
          -  Patients who took medicines for clinical trials in other clinical trials within four&#xD;
             weeks of document consent&#xD;
&#xD;
          -  Patients who are unable to participate in clinical trials on the judgment of other&#xD;
             researchers&#xD;
&#xD;
          -  Patients who cannot read the consent form (e.g. illiteracy, foreigners, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung Up Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung Up Kim</last_name>
    <phone>+82-2228-1982</phone>
    <email>ksukorea@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jung il Lee</last_name>
      <phone>82-10-2218-9331</phone>
      <email>mdflorence@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Won seok Kang</last_name>
      <phone>82-10-8750-5033</phone>
      <email>wonseok1202.kang@samsung.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Su jong Yu</last_name>
      <phone>82-2-2072-2228</phone>
      <email>ydoctor2@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seung Up Kim</last_name>
      <phone>+82-2228-1982</phone>
      <email>ksukorea@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

